These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 25065013)

  • 61. Current therapy of systemic sclerosis (scleroderma).
    Müller-Ladner U; Benning K; Lang B
    Clin Investig; 1993 Apr; 71(4):257-63. PubMed ID: 8471811
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Systemic sclerosis in 2017].
    Soukup T; Veleta T
    Vnitr Lek; 2018; 64(2):146-154. PubMed ID: 29595279
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.
    Motegi S; Toki S; Yamada K; Uchiyama A; Ishikawa O
    J Dermatol; 2015 Feb; 42(2):189-92. PubMed ID: 25483258
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review.
    Tan A; Denton CP; Mikhailidis DP; Seifalian AM
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S66-74. PubMed ID: 21586221
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

  • 66. First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study.
    Rubio-Rivas M; Corbella X; Pestaña-Fernández M; Tolosa-Vilella C; Guillen-Del Castillo A; Colunga-Argüelles D; Trapiella-Martínez L; Iniesta-Arandia N; Castillo-Palma MJ; Sáez-Comet L; Egurbide-Arberas MV; Ortego-Centeno N; Freire M; Vargas-Hitos JA; Ríos-Blanco JJ; Todolí-Parra JA; Rodríguez-Carballeira M; Marín-Ballvé A; Segovia-Alonso P; Pla-Salas X; Madroñero-Vuelta AB; Ruiz-Muñoz M; Fonollosa-Pla V; Simeón-Aznar CP; ; Callejas Moraga E; Calvo E; Carbonell C; Castillo MJ; Chamorro AJ; Colunga D; Corbella X; Egurbide MV; Espinosa G; Fonollosa V; Freire M; García Hernández FJ; González León R; Guillén Del Castillo A; Iniesta N; Lorenzo R; Madroñero AB; Marí B; Marín A; Ortego-Centeno N; Pérez Conesa M; Pestaña M; Pla X; Ríos Blanco JJ; Rodríguez Carballeira M; Rubio Rivas M; Ruiz Muñoz M; Sáez Comet L; Segovia P; Simeón CP; Soto A; Tarí E; Todolí JA; Tolosa C; Trapiella L; Vargas Hitos JA; Verdejo G
    Clin Rheumatol; 2018 Apr; 37(4):999-1009. PubMed ID: 29214548
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Systemic and localized scleroderma.
    Chung L; Lin J; Furst DE; Fiorentino D
    Clin Dermatol; 2006; 24(5):374-92. PubMed ID: 16966019
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Emerging drugs and therapeutics for systemic sclerosis.
    Lee JJ; Pope JE
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Assessment of vascular involvement.
    Kahaleh B; Meyer O; Scorza R
    Clin Exp Rheumatol; 2003; 21(3 Suppl 29):S9-14. PubMed ID: 12889215
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Systemic Sclerosis with Focus on Scleroderma Renal Crisis.
    Pasha F; Abazari S; Bikarannejad P; Zabolian A
    Iran J Kidney Dis; 2019 May; 13(3):207-210. PubMed ID: 31209194
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Raynaud's phenomenon.
    Herrick AL; Wigley FM
    Best Pract Res Clin Rheumatol; 2020 Feb; 34(1):101474. PubMed ID: 32007400
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cystic lung disease in systemic sclerosis: a case report with high resolution computed tomography findings.
    Bergemann A; Tikly M
    Rev Rhum Engl Ed; 1996 Mar; 63(3):213-5. PubMed ID: 8731240
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
    Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis.
    Farina N; Campochiaro C; Lescoat A; Benanti G; De Luca G; Khanna D; Dagna L; Matucci-Cerinic M
    Expert Rev Clin Immunol; 2023; 19(9):1131-1142. PubMed ID: 37366065
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis.
    Hughes M; Ong VH; Anderson ME; Hall F; Moinzadeh P; Griffiths B; Baildam E; Denton CP; Herrick AL
    Rheumatology (Oxford); 2015 Nov; 54(11):2015-24. PubMed ID: 26116156
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Iloprost for the treatment of systemic sclerosis].
    Hachulla E; Launay D; Hatron PY
    Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Emerging targeted therapies in scleroderma lung and skin fibrosis.
    Maurer B; Distler O
    Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts.
    Rabquer BJ; Koch AE
    Curr Rheumatol Rep; 2012 Feb; 14(1):56-63. PubMed ID: 22083296
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The vasculopathy of Raynaud's phenomenon and scleroderma.
    Flavahan NA; Flavahan S; Mitra S; Chotani MA
    Rheum Dis Clin North Am; 2003 May; 29(2):275-91, vi. PubMed ID: 12841295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.